Cinetto Francesco, Compagno Nicolò, Scarpa Riccardo, Malipiero Giacomo, Agostini Carlo
Clinical Immunology, Department of Medicine-DIMED, Padova University Hospital, via Giustiniani 2, 35128 Padua, Italy.
Clin Mol Allergy. 2015 Sep 1;13(1):19. doi: 10.1186/s12948-015-0025-9. eCollection 2015.
Sarcoidosis is a granulomatous disease whose outcome varies from spontaneous remission to chronic refractory disease. Provided that steroids represent the gold standard as a first line treatment, many immune suppressants drugs are currently used in the disease management. However, refractory disease is still a great challenge. Rituximab is an anti-CD20 chimeric monoclonal antibody, currently used for the treatment of B cell malignancies and systemic autoimmune diseases. There are few case reports describing the successful use of Rituximab in refractory sarcoidosis with lung, eye, lymph nodes and skin involvement. In this paper we described three different case reports in which Rituximab has been used to treat refractory sarcoidosis and we reviewed the existing literature.
结节病是一种肉芽肿性疾病，其病情转归从自发缓解到慢性难治性疾病不等。鉴于类固醇是一线治疗的金标准，目前许多免疫抑制药物用于该病的管理。然而，难治性疾病仍然是一个巨大的挑战。利妥昔单抗是一种抗CD20嵌合单克隆抗体，目前用于治疗B细胞恶性肿瘤和全身性自身免疫性疾病。很少有病例报告描述利妥昔单抗成功用于治疗累及肺、眼、淋巴结和皮肤的难治性结节病。在本文中，我们描述了三例使用利妥昔单抗治疗难治性结节病的不同病例报告，并对现有文献进行了综述。
